Innovating to overcome disease

Committed to developing medicines to meaningfully improve the probability of survival for people facing deadly diseases. 


A new class of selective therapies demonstrating potential against gliomas, leukemia and other cancers


Groundbreaking therapy in treatment of acute myeloid leukemia (AML)

TEMBEXA® (brincidofovir)

The first antiviral approved for the treatment of smallpox in all age groups

Accelerating Innovation

Chimerix is continuously evaluating innovative ways to overcome deadly and difficult-to-treat diseases. Learn more about our approach to investing in novel drug candidates that meaningfully improve the probability of survival and the collaborative team driving the development of these promising new therapies.

TEMBEXA® Approval

Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox

More about TEMBEXA® Approval

Our Latest Acquisition

Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program

Acquisition Details